Edgar Filing: OMEROS CORP - Form 8-K

OMEROS CORP Form 8-K July 07, 2011

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

#### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 30, 2011

### **OMEROS CORPORATION**

(Exact name of registrant as specified in its charter)

Washington (State or other jurisdiction

001-34475 (Commission 91-1663741 (IRS Employer

of incorporation) File Number) Identification No.)

#### Edgar Filing: OMEROS CORP - Form 8-K

1420 Fifth Avenue, Suite 2600

Seattle, Washington 98101

(Address of principal executive offices, including zip code)

(206) 676-5000

(Registrant s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

On June 30, 2011, Jean-Philippe Tripet, a member of the board of directors of Omeros Corporation, submitted his resignation as a director effective immediately. As the chairman and managing partner of Aravis Venture, a Switzerland-based venture capital firm, Mr. Tripet has resigned to allow him to focus on Aravis early-stage portfolio companies. Mr. Tripet s resignation is not a result of any disagreement with Omeros or any matter relating to Omeros operations, policies or practices.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### OMEROS CORPORATION

By: /s/ Gregory A. Demopulos Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors

Date: July 7, 2011